These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 11857958)

  • 1. [Studies on the risk factors for fenofibrate-induced elevation of liver function tests].
    Hayakawa T; Hayashi A; Miyakawa M; Shimoyama K; Sekiya S; Sekiguchi M; Inotsume N
    Yakugaku Zasshi; 2002 Feb; 122(2):169-75. PubMed ID: 11857958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenofibrate-induced acute cholestatic hepatitis.
    Ho CY; Kuo TH; Chen TS; Tsay SH; Chang FY; Lee SD
    J Chin Med Assoc; 2004 May; 67(5):245-7. PubMed ID: 15357112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute cholestatic hepatitis induced by fenofibrate.
    Hajdu D; Aiglová K; Vinklerová I; Urbánek K
    J Clin Pharm Ther; 2009 Oct; 34(5):599-602. PubMed ID: 19744016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acute hepatitis and drug dermatitis due to fenofibrate (Secalip)].
    Fartoux-Heymann L; Narcy-Lambare B; Labayle D; Fischer D
    Ann Med Interne (Paris); 2001 Sep; 152(5):353-4. PubMed ID: 11593148
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.
    Ishibashi S; Arai H; Yokote K; Araki E; Suganami H; Yamashita S;
    J Clin Lipidol; 2018; 12(1):173-184. PubMed ID: 29203092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological variations in hyperlipidemic children and adolescents treated with fenofibrate.
    Steinmetz J; Morin C; Panek E; Siest G; Drouin P
    Clin Chim Acta; 1981 Apr; 112(1):43=53. PubMed ID: 6113065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fenofibrate-Induced elevation in serum creatinine.
    Ritter JL; Nabulsi S
    Pharmacotherapy; 2001 Sep; 21(9):1145-9. PubMed ID: 11560205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and Characterization of Fenofibrate-Induced Liver Injury.
    Ahmad J; Odin JA; Hayashi PH; Chalasani N; Fontana RJ; Barnhart H; Cirulli ET; Kleiner DE; Hoofnagle JH
    Dig Dis Sci; 2017 Dec; 62(12):3596-3604. PubMed ID: 29119413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Painful acute liver involvement related to ingestion of fenofibrate].
    Rouhier ML; Rifflet H; Rifflet I; Oberti F; Vuillemin E; Chevailler A; Calès P
    Gastroenterol Clin Biol; 1996; 20(12):1137-8. PubMed ID: 9033862
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of fenofibrate on lipoprotein(a) in hypertriglyceridemic patients: impact of change in triglyceride level and liver function.
    Ko HS; Kim CJ; Ryu WS
    J Cardiovasc Pharmacol; 2005 Oct; 46(4):405-11. PubMed ID: 16160590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Acute cytolytic and cholestatic hepatitis induced by fenofibrate].
    Pichon N; Vincensini JF; Rozière A; Labrousse F; Sautereau D; Pillegand B
    Gastroenterol Clin Biol; 2003 Oct; 27(10):947-9. PubMed ID: 14631314
    [No Abstract]   [Full Text] [Related]  

  • 12. Fenofibrate-induced hepatotoxicity: A case with a special feature that is different from those in the LiverTox database.
    Ma S; Liu S; Wang Q; Chen L; Yang P; Sun H
    J Clin Pharm Ther; 2020 Feb; 45(1):204-207. PubMed ID: 31518450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hepatitis caused by fenofibrate].
    Massen H; Furet Y
    Cah Anesthesiol; 1986 May; 34(3):249-50. PubMed ID: 3742311
    [No Abstract]   [Full Text] [Related]  

  • 14. PPAR-alpha agonist treatment increases trefoil factor family-3 expression and attenuates apoptosis in the liver tissue of bile duct-ligated rats.
    Karakan T; Kerem M; Cindoruk M; Engin D; Alper M; Akın O
    Turk J Gastroenterol; 2013; 24(2):134-40. PubMed ID: 23934460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.
    Duan W; Ou X; Wang X; Wang Y; Zhao X; Wang Q; Wu X; Zhang W; Ma H; You H; Jia J
    Rev Esp Enferm Dig; 2018 Sep; 110(9):557-563. PubMed ID: 29739227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease.
    Fernández-Miranda C; Pérez-Carreras M; Colina F; López-Alonso G; Vargas C; Solís-Herruzo JA
    Dig Liver Dis; 2008 Mar; 40(3):200-5. PubMed ID: 18261709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment.
    Zhao S; Wang F; Dai Y; Lin L; Tong Q; Liao Y; Yin Y; Wang G; Yan Y; Li X; Wang D; Wei P; Cheng X; Xie Q; Sun Y; Fu G; Huang H; Dong Y; Liu J; Yan J; Yan L; Cui S; Liu X; Li Z; Chen H; Hu T; Gong H
    Int J Cardiol; 2016 Oct; 221():832-6. PubMed ID: 27434354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of adverse events with fibrates.
    Alsheikh-Ali AA; Kuvin JT; Karas RH
    Am J Cardiol; 2004 Oct; 94(7):935-8. PubMed ID: 15464682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hepatitis induced by fibrates].
    Tudesq N; Bentournes M
    Ann Biol Clin (Paris); 2006; 64(5):515-6. PubMed ID: 17124754
    [No Abstract]   [Full Text] [Related]  

  • 20. A comparative research on obesity hypertension by the comparisons and associations between waist circumference, body mass index with systolic and diastolic blood pressure, and the clinical laboratory data between four special Chinese adult groups.
    Wu O; Leng JH; Yang FF; Yang HM; Zhang H; Li ZF; Zhang XY; Yuan CD; Li JJ; Pan Q; Liu W; Ren YJ; Liu B; Liu QM; Cao CJ
    Clin Exp Hypertens; 2018; 40(1):16-21. PubMed ID: 29083240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.